Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
- Medicinal cannabis: what next for Brazil? 21-10-2019
- Pharma: A Mexican tradeoff 30-09-2019
- Secondary patents: Moscow mewl 30-09-2019
- The future of precision medicine part 6: reimbursement 08-08-2019
- Shire Pharmaceuticals: A culture of excellence 21-05-2019
Latest generics news
FDA warns of ‘grave’ knock-on effects from Eagle decision
29-05-2020
The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
FDA approves Hikma’s Vascepa generic
26-05-2020
